Reported research findings
- No established human clinical trials define efficacy or safety in people to date.
WEIGHT & METABOLIC RESEARCH
SLU-PP-332
A synthetic ERR pan-agonist studied in models as an exercise mimetic.
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, β, and γ). Often called an exercise mimetic, it activates metabolic pathways associated with endurance training—mitochondrial biogenesis, fatty-acid oxidation, and energy expenditure—in preclinical models. Evidence to date is preclinical, with no established human trials.
Why BLP features SLU-PP-332
Included as an early-stage research compound with a specific ERR-receptor mechanism and interesting exercise-mimetic modeling. Evidence is preclinical and its real-world use history is minimal, so it is clearly presented as experimental.
Mechanism
Potently activates ERRα/β/γ receptors, mimicking transcriptional programs associated with aerobic exercise.
Increases mitochondrial biogenesis and oxidative capacity in skeletal muscle models.
Shifts muscle fibers toward more oxidative (fat-burning) types and enhances fatty-acid oxidation independent of food intake or activity.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- In obese models: reduced fat-mass accumulation and progressive body-fat loss with no change in appetite.
- Reported increased endurance capacity and mitochondrial efficiency.
- Reported better body composition with preserved muscle in models.
- Preclinical animal studies reported a favorable short-term safety profile at research doses; reported effects can include increased warmth or sweating from elevated metabolism.
Regulatory status
SLU-PP-332 is investigational with preclinical evidence only and no established human trials. Sold and offered strictly for laboratory and research use.